Items without sitelinks
From determinar.ia.br - Determine suas informações
Showing below up to 50 results in range #9,551 to #9,600.
- Necrosis of orbit (Q103259)
- Pancreatitis due to hyperlipidaemia (Q103258)
- Acute pancreatitis due to infection, with systemic complication (Q103257)
- Acute pancreatitis due to systemic disease, with local and systemic complication (Q103256)
- Chronic orbital myositis (Q103255)
- Pancreatitis due to vasculitis (Q103254)
- Tenonitis of eye (Q103253)
- Potassium-aggravated myotonia (Q103252)
- Acute pancreatitis due to systemic disease, with local complication (Q103251)
- Ischaemic acute pancreatitis, with local and systemic complication (Q103250)
- Pseudotumor of orbit (Q103249)
- Ischaemic acute pancreatitis, with local complication (Q103248)
- Abscess of pancreas (Q103247)
- Acute pancreatitis due to infection, with local and systemic complication (Q103246)
- Acute recurrent haemorrhagic pancreatitis (Q103245)
- Acute pancreatitis due to infection, with local complication (Q103244)
- Laceration of eyebrow (Q103243)
- Intentional self-harm by exposure to or harmful effects of stimulant laxatives (Q103242)
- Maternal care for ABO isoimmunisation (Q103241)
- Intentional self-harm by exposure to or harmful effects of histamine H2-receptor blockers (Q103240)
- Intentional self-harm by exposure to or harmful effects of emetics (Q103239)
- Intentional self-harm by exposure to or harmful effects of other antacids or anti-gastric-secretion drugs (Q103238)
- Intentional self-harm by exposure to or harmful effects of peripheral vasodilators (Q103237)
- Intentional self-harm by exposure to or harmful effects of antidiarrhoeal drugs (Q103236)
- Intentional self-harm by exposure to or harmful effects of angiotensin-converting-enzyme inhibitors (Q103235)
- Intentional self-harm by exposure to or harmful effects of digestants (Q103234)
- Intentional self-harm by exposure to or harmful effects of nitroglycerin, nitroglycerol, medicinal (Q103233)
- Intentional self-harm by exposure to or harmful effects of saline or osmotic laxatives (Q103232)
- Intentional self-harm by exposure to or harmful effects of other laxatives (Q103231)
- Intentional self-harm by exposure to or harmful effects of antihyperlipidemic or antiarteriosclerotic drugs (Q103230)
- Intentional self-harm by exposure to or harmful effects of other antihypertensive drugs (Q103229)
- Intentional self-harm by exposure to or harmful effects of antivaricose drugs, including sclerosing agents (Q103228)
- Intentional self-harm by exposure to or harmful effects of other antidysrhythmic drugs (Q103227)
- Intentional self-harm by exposure to or harmful effects of cardiac-stimulant glycosides or drugs of similar action (Q103226)
- Intentional self-harm by exposure to or harmful effects of calcium-channel blockers (Q103225)
- Intentional self-harm by exposure to or harmful effects of other coronary vasodilators (Q103224)
- Fatty nervous system degeneration (Q103223)
- Intentional self-harm by exposure to or harmful effects of aminoglycosides (Q103222)
- Intentional self-harm by exposure to or harmful effects of macrolides (Q103221)
- Intentional self-harm by exposure to or harmful effects of beta-adrenoreceptor antagonists (Q103220)
- Intentional self-poisoning by and exposure to other drugs acting on the autonomic nervous system (Q103219)
- Intentional self-harm by exposure to or harmful effects of penicillins (Q103218)
- Intentional self-harm by exposure to or harmful effects of alpha-adrenoreceptor antagonists (Q103217)
- Intentional self-harm by exposure to or harmful effects of salbutamol (Q103216)
- Intentional self-harm by exposure to or harmful effects of antifungal antibiotics, systemically used (Q103215)
- Intentional self-harm by exposure to or harmful effects of other parasympatholytics or spasmolytics (Q103214)
- Intentional self-harm by exposure to or harmful effects of rifampicin (Q103213)
- Intentional self-harm by exposure to or harmful effects of expectorants (Q103212)
- Intentional self-harm by exposure to or harmful effects of predominantly beta-adrenoreceptor agonists (Q103211)
- Intentional self-harm by exposure to or harmful effects of antiasthmatics, not elsewhere classified (Q103210)
